New York, April 27, 2026 — Transcend Therapeutics, a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric conditions, announced that the U.S. Food and Drug Administration (FDA) has awarded the company a national priority voucher in connection with Transcend’s development of TSND-201 (methylone) for the treatment of post-traumatic stress disorder (PTSD).
The voucher was issued as part of the FDA’s broader initiative to accelerate the development of treatments for serious mental health conditions.
“This recognition further underscores the urgent and significant unmet need in PTSD and the potential for TSND-201 to become a rapid-acting and durable treatment option,” said Transcend Therapeutics Co-Founder and CEO Blake Mandell. “We look forward to continuing to collaborate closely with the FDA as we undertake our rigorous Phase 3 clinical program with the goal of bringing new treatment options to patients.”
TSND-201 previously received Breakthrough Therapy Designation from the FDA in July 2025, reflecting encouraging clinical data and the significant unmet need in PTSD. The company is currently enrolling patients in its Phase 3 clinical trial in the U.S.
About PTSD
Post‑traumatic stress disorder is a serious mental health condition that develops after experiencing or witnessing a life‑threatening event or a deeply traumatic experience. Common symptoms include flashbacks, nightmares, severe anxiety, and uncontrollable thoughts related to the traumatic event.
In the U.S., it is estimated that more than 13 million people live with PTSD each year,¹ and nearly 6 out of every 100 individuals are expected to be diagnosed with PTSD at some point in their lives. Only two medications are FDA-approved for the treatment of PTSD (sertraline and paroxetine), and novel treatments for PTSD are urgently needed.
About TSND-201
TSND-201 (methylone) is a rapid-acting neuroplastogen developed by Transcend. TSND-201 has well-characterized primary pharmacology, with its primary site of action at the monoamine transporters, and no activity at 5-HT2A receptors (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications. TSND-201 is an investigational medication.
About Transcend Therapeutics
Transcend, founded in 2021 and based in New York City, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. The company’s mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. In March 2026, Transcend Therapeutics and Otsuka Pharmaceutical Co., Ltd. announced plans for Otsuka to acquire Transcend.
1. U.S. Department of Veteran Affairs. PTSD: National Center for PTSD. https://www.ptsd.va.gov/understand/common/common_adults.asp
Contact: press@transcendtherapeutics.com
